CN107952003A - A kind of ginkgo leaf monascus health product and preparation method thereof - Google Patents
A kind of ginkgo leaf monascus health product and preparation method thereof Download PDFInfo
- Publication number
- CN107952003A CN107952003A CN201711003574.4A CN201711003574A CN107952003A CN 107952003 A CN107952003 A CN 107952003A CN 201711003574 A CN201711003574 A CN 201711003574A CN 107952003 A CN107952003 A CN 107952003A
- Authority
- CN
- China
- Prior art keywords
- monascus
- parts
- health product
- ginkgo leaf
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000008100 Ginkgo biloba Nutrition 0.000 title claims abstract description 75
- 235000011201 Ginkgo Nutrition 0.000 title claims abstract description 49
- 230000036541 health Effects 0.000 title claims abstract description 43
- 241000228347 Monascus <ascomycete fungus> Species 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000218628 Ginkgo Species 0.000 title claims abstract 17
- 238000004519 manufacturing process Methods 0.000 title description 3
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 59
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 32
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 30
- 229920002472 Starch Polymers 0.000 claims abstract description 19
- 239000008107 starch Substances 0.000 claims abstract description 19
- 235000019698 starch Nutrition 0.000 claims abstract description 19
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 18
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 18
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 18
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 52
- 238000000576 coating method Methods 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 21
- 239000011122 softwood Substances 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 20
- 235000013339 cereals Nutrition 0.000 claims description 18
- 238000009501 film coating Methods 0.000 claims description 18
- 239000007888 film coating Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 16
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 235000020985 whole grains Nutrition 0.000 claims description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
- 229940032147 starch Drugs 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 7
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 238000007493 shaping process Methods 0.000 claims description 5
- 239000004408 titanium dioxide Substances 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 4
- 230000006641 stabilisation Effects 0.000 abstract description 3
- 238000011105 stabilization Methods 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229960001866 silicon dioxide Drugs 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000034710 Cerebral arteriovenous malformation Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000002263 Intracranial Arteriovenous Malformations Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HGWOWDFNMKCVLG-UHFFFAOYSA-N [O--].[O--].[Ti+4].[Ti+4] Chemical compound [O--].[O--].[Ti+4].[Ti+4] HGWOWDFNMKCVLG-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 201000000034 arteriovenous malformations of the brain Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of ginkgo leaf monascus health product, including following components in percentage by weight：40 60 parts of ginkgo biloba p.e；120 170 parts of red yeast rice；140 210 parts of starch；80 130 parts of maltodextrin；75 130 parts of D-sorbite；7 15 parts of magnesium stearate.The ginkgo leaf monascus health product selects suitable auxiliary material using ginkgo biloba p.e and red yeast rice as raw material, and adjusts suitable supplementary material proportioning, and product safety, the stabilization of acquisition, have auxiliary effect for reducing blood fat, disclosure satisfy that the demand of Hyperlipidemia crowd.The invention also discloses a kind of preparation method of ginkgo leaf monascus health product, flow is simple, easy to operate, and processing safety is high.
Description
Technical field
The present invention relates to health product technology field, more particularly to a kind of ginkgo leaf monascus health product and preparation method thereof.
Background technology
Ginkgo (Ginkgo biloba L.), is Ginkgoaceae, Ginkgo deciduous tree, and ginkgo is also known as maidenhair tree, Gong Sunshu,
And ginkgo leaf generally refers to ginkgo dried leaf.When in the fall, still green ginkgo leaf is harvested, dry in time, obtained ginkgo leaf
Nature and flavor are sweet, bitter, puckery, put down, distributed in heart and lung channels, have plurality of health care functions, such as：Increase cerebrovascular flow, reduce cerebral vascular resistance,
Improving Cerebrovascular disorders function, protect brain cell from ischemic damage, coronary artery dilator, prevents angina pectoris and miocardial infarction,
Suppress platelet aggregation, prevent thrombosis, reducing blood lipid, removes harmful oxyradical etc..
In addition, red yeast rice nature and flavor sweet, warm, enters liver, spleen, large intestine channel, it is a kind of aboundresources, safe natural pigment.
The Lovastatin (Lovastatin) extracted from red yeast rice plays the role of norcholesterol.
Ginkgo leaf is equipped with red yeast rice, can be promoting blood circulation and removing blood stasis, is prevented for hyperlipidemia.
But lack a kind of scientific formulation, effect on the market now significantly to aid in guarantor of the reducing blood lipid as major function
Health food, if using ginkgo biloba p.e and red yeast rice as raw material, has been prepared into auxiliary lipid-lowering function, and effective guarantor
Strong product, this will have epoch-making meaning to health.
The content of the invention
For overcome the deficiencies in the prior art, it is an object of the present invention to providing a kind of ginkgo leaf monascus health product,
Using ginkgo biloba p.e and red yeast rice as raw material, suitable auxiliary material is selected, and adjusts suitable supplementary material proportioning, the product peace of acquisition
Entirely, stablize, there is auxiliary effect for reducing blood fat, disclosure satisfy that the demand of Hyperlipidemia crowd.
The second object of the present invention is to provide a kind of preparation method of ginkgo leaf monascus health product, and flow is simple, operation
Simplicity, processing safety are high.
An object of the present invention adopts the following technical scheme that realization：
A kind of ginkgo leaf monascus health product, including following components in percentage by weight：
40-60 parts of ginkgo biloba p.e；120-170 parts of red yeast rice；140-210 parts of starch；
80-130 parts of maltodextrin；75-130 parts of D-sorbite；7-15 parts of magnesium stearate.
Further, including in percentage by weight following components：
45-55 parts of ginkgo biloba p.e；130-160 parts of red yeast rice；150-200 parts of starch；
90-120 parts of maltodextrin；85-120 parts of D-sorbite；8-13 parts of magnesium stearate.
Further, 13-23 parts of film coating pre-mix doses are further included.
Further, the prepared composition of the film coating pre-mix dose includes：Hydroxypropyl methylcellulose, polyethylene glycol, dioxy
Change titanium and Brown Ferric Oxide.
Further, the formulation of the ginkgo leaf monascus health product is：Pulvis, tablet, granule, capsule, solution,
Emulsion or supensoid agent.
The second object of the present invention adopts the following technical scheme that realization：
A kind of preparation method of ginkgo leaf monascus health product, including：
Batch mixing step：The ginkgo biloba p.e of formula ratio, red yeast rice, starch, maltodextrin and D-sorbite are mixed
Uniformly, the first mixture is obtained；
Softwood step processed：Add water in first mixture, while adding waterside to stir, obtain softwood；
Granulation step：The softwood is prepared into graininess, obtains wet grain；
Drying steps：The wet grain is dried, obtains dry granular；
Secondary blend step：The magnesium stearate of formula ratio and the dry granular are mixed, obtain the second mixture；
Forming step：Second mixture is prepared into preset shape, obtains the ginkgo leaf monascus health product.
Further, sifting step is further included：Respectively by ginkgo biloba p.e, red yeast rice, starch, maltodextrin and sorbose
Alcohol crosses 80 mesh sieves, then weighs above-mentioned each component according to formula ratio respectively, in case into a batch mixing step.
Further, whole grain step is further included：After the drying steps obtain dry granular, the dry granular is crossed into 16 mesh
Sieve, carries out whole grain, enters the secondary blend step after whole grain.
Further, in a batch mixing step, the ginkgo biloba p.e of formula ratio, red yeast rice, starch, malt are pasted
In essence and D-sorbite input two-dimensional motion mixer, 18-22min is mixed；
In the softwood step processed, first mixture is added in trough type mixing machine, then adds water, and side adds
Waterside is stirred, and obtains softwood；
In the granulation step, the softwood is placed in oscillating granulator, after 16 mesh nylon mesh, is obtained wet
Grain；
In the drying steps, the wet grain is sent into HighefficientFluidbeddrier, it is 45-55 to control drying temperature
DEG C, the dry moisture to wet grain stops drying when being down to less than 5%, obtains dry granular；
In the secondary blend step, the magnesium stearate of formula ratio and the dry granular are placed in mixer, mix 18-
22min, obtains the second mixture；
In the forming step, second mixture is placed in closed rotary pelleting machine, carries out tabletting, often
13-17min claims once piece weight, controls average piece to focus in ± the 5% of default piece weight, hardness is controlled in 7-9 kilograms, tabletting knot
Beam.
Further, coating steps are further included, take 50% ethanol solution, film coating pre-mix dose is poured into 50% second
It is stirring while adding in alcoholic solution, obtain coating solution；The second mixture after the coating solution and shaping is placed in seed-coating machine,
It is coated, obtains final ginkgo leaf monascus health product.
Compared with prior art, the beneficial effects of the present invention are：
(1) ginkgo leaf monascus health product provided by the present invention, using ginkgo biloba p.e and red yeast rice as critical materials, selection
Suitable auxiliary material, including sweetener, lubricant, match, obtained product safety, stabilization by adjusting suitable supplementary material, tool
There is auxiliary effect for reducing blood fat, disclosure satisfy that the demand of Hyperlipidemia crowd.
(2) preparation method of ginkgo leaf monascus health product provided by the present invention, flow is simple, easy to operate, operation peace
Quan Xinggao.
Embodiment
In the following, with reference to embodiment, the present invention is described further, it is necessary to which explanation is, what is do not collided
Under the premise of, new embodiment can be formed between various embodiments described below or between each technical characteristic in any combination.
A kind of ginkgo leaf monascus health product, including following components in percentage by weight：
40-60 parts of ginkgo biloba p.e；120-170 parts of red yeast rice；140-210 parts of starch；
80-130 parts of maltodextrin；75-130 parts of D-sorbite；7-15 parts of magnesium stearate.
Red yeast rice is a kind of aboundresources, safe natural pigment；Ginkgo biloba p.e has plurality of health care functions, right
The diseases such as treatment coronary heart diseases and angina pectoris, cerebral arteriovenous malformation, senile dementia, hypertension have magical curative effect.
As further embodiment, 13-23 parts of film coating pre-mix doses are further included.
As further embodiment, the prepared composition of film coating pre-mix dose includes：Hydroxypropyl methylcellulose, poly- second two
Alcohol, titanium dioxide and Brown Ferric Oxide, the coating pre-mixing agent obtained by mentioned component are stomach dissolution type.Above-mentioned film-coating premixing
Agent can be obtained by commercially available channel, such as Anhui Shanhe Medicinal Subsidiary Material Co., Ltd..
As further embodiment, the formulation of ginkgo leaf monascus health product is：Pulvis, tablet, granule, capsule
Agent, solution, emulsion or supensoid agent, types of formulation is unlimited, but preferably piece shape, obtains ginkgo leaf red yeast rice piece.
The ginkgo leaf monascus health product that the embodiment of the present invention is provided, using ginkgo biloba p.e and red yeast rice as critical materials,
Starch, maltodextrin, D-sorbite, magnesium stearate, film coating pre-mix dose (hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide
Titanium, Brown Ferric Oxide) it is made of auxiliary material, each component compatibility is proper, and product safety, stabilization, effect are obvious, the experiment proved that, energy
Effectively achieve the purpose that to aid in reducing blood lipid, meet the needs of Hyperlipidemia crowd.
A kind of preparation method of ginkgo leaf monascus health product, including：
Batch mixing step：The ginkgo biloba p.e of formula ratio, red yeast rice, starch, maltodextrin and D-sorbite are mixed
Uniformly, the first mixture is obtained；
Softwood step processed：Add water in the first mixture, while adding waterside to stir, obtain softwood；
Granulation step：Softwood is prepared into graininess, obtains wet grain；
Drying steps：Wet grain is dried, obtains dry granular；
Secondary blend step：The magnesium stearate of formula ratio and dry granular are mixed, obtain the second mixture；
Forming step：Second mixture is prepared into preset shape, obtains ginkgo leaf monascus health product.
As further embodiment, sifting step is further included：Respectively by ginkgo biloba p.e, red yeast rice, starch, malt
Dextrin and D-sorbite cross 80 mesh sieves, then weigh above-mentioned each component according to formula ratio respectively, in case into a batch mixing step.
As further embodiment, whole grain step is further included：After drying steps obtain dry granular, dry granular is crossed 16
Mesh sieve, carries out whole grain, enters secondary blend step after whole grain.
As further embodiment, in a batch mixing step, by the ginkgo biloba p.e, red yeast rice, shallow lake of formula ratio
In powder, maltodextrin and D-sorbite input two-dimensional motion mixer, 18-22min is mixed；
In softwood step processed, the first mixture is added in trough type mixing machine, then adds water, and side adds waterside to stir
Mix, obtain softwood；
In granulation step, softwood is placed in oscillating granulator, after 16 mesh nylon mesh, obtains wet grain；
In drying steps, wet grain is sent into HighefficientFluidbeddrier, it is 45-55 DEG C to control drying temperature, and drying is extremely
The moisture of wet grain stops drying when being down to less than 5%, obtains dry granular；
In secondary blend step, the magnesium stearate of formula ratio and dry granular are placed in mixer, 18-22min is mixed, obtains
To the second mixture；
In forming step, the second mixture is placed in closed rotary pelleting machine (special-shaped punch die), carries out tabletting, often
13-17min claims once piece weight, controls average piece to focus in ± the 5% of default piece weight, hardness is controlled in 7-9 kilograms, tabletting knot
Beam；Wherein, it is preferably again 0.6g/ pieces to preset piece, after tabletting, is contained and is capped with the turnover barrel of dried and clean and sealed, and is claimed
Weight, bucket outer patch distinguishing mark.
As further embodiment, coating steps are further included, 50% ethanol solution is taken, film coating pre-mix dose is fallen
Enter in 50% ethanol solution, it is stirring while adding, obtain coating solution；The second mixture after coating solution and shaping is placed in seed-coating machine
It is interior, it is coated, obtains final ginkgo leaf monascus health product.After coating, Multifunctional protective sheath is formed on the surface of product.
It is first that stomach dissolution type pharmaceutical films coating premix is auxiliary in the coating steps as further embodiment
Expect (hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and Brown Ferric Oxide) by formula solid content 8% and technique gain in weight 3%
It is required that precise；Then 50% ethanol solution is configured to edible alcohol and purified water, 50% ethanol solution of precise is standby
With；Then stomach dissolution type film-coating premixing auxiliary material is poured slowly into 50% solution, it is stirring while adding, at the uniform velocity stir, be configured to
Solid content is 8% uniform coating solution；
After label (the second mixture after shaping) sampling Detection qualification, film coating in high-efficiency coating machine is put.Tried outside machine
Spray gun, starts into atomization, it is desirable to choice refreshments：Preheating time 1min, rotating speed 6r/min, 65 DEG C of design temperature, piece bed tempertaure 38-40
DEG C, 65 DEG C of inlet air temperature, 40 DEG C of leaving air temp, throw 20cm.Coating process operating personnel cannot leave, concern temperature, revolution,
Spray gun is atomized situation, cannot pause halfway；Before off the pot, stop heating, turn 20min, revolution 3r/ again after being cooled to room temperature
min；Finally dress cloth bag carries out the piece 24h that dries in the air, and is put into silica-gel desiccant, barrelling is to be packed.
It is specific embodiment of the present invention below, used raw material, equipment etc. remove special limit in the following embodiments
It can be obtained outside fixed by buying pattern.
Embodiment 1-5
A kind of ginkgo leaf monascus health product, including following components：Ginkgo biloba p.e, red yeast rice, starch, maltodextrin, mountain
Pears sugar alcohol, magnesium stearate and film coating pre-mix dose, wherein, the prepared composition of film coating pre-mix dose includes hypromellose
Element, polyethylene glycol, titanium dioxide and Brown Ferric Oxide；Specifying information see the table below 1.
The formula table of 1 embodiment 1-5 ginkgo leaf monascus health products of table
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | |
| Ginkgo biloba p.e | 40 | 45 | 50 | 55 | 60 |
| Red yeast rice | 120 | 140 | 160 | 170 | 130 |
| Starch | 140 | 160 | 210 | 180 | 200 |
| Maltodextrin | 80 | 130 | 120 | 90 | 100 |
| D-sorbite | 130 | 75 | 85 | 120 | 100 |
| Magnesium stearate | 13 | 8 | 15 | 10 | 7 |
| Film coating pre-mix dose | 13 | 18 | 23 | 20 | 0 |
The preparation method of above-mentioned ginkgo leaf monascus health product is as follows：
Sifting step：Ginkgo biloba p.e, red yeast rice, starch, maltodextrin and D-sorbite are crossed into 80 mesh sieves respectively, then
Respectively above-mentioned each component is weighed according to formula ratio；
Batch mixing step：The ginkgo biloba p.e of formula ratio, red yeast rice, starch, maltodextrin and D-sorbite are put into
In two-dimensional motion mixer, 20min is mixed, obtains the first mixture；
Softwood step processed：First mixture is added in trough type mixing machine, then adds water, and side adds waterside to stir, and obtains
To softwood；
Granulation step：Softwood is placed in oscillating granulator, after 16 mesh nylon mesh, obtains wet grain；
Drying steps：Wet grain is sent into HighefficientFluidbeddrier, it is 45-55 DEG C to control drying temperature, dry to wet grain
Moisture stop drying when being down to less than 5%, obtain dry granular；
Whole grain step：After drying steps obtain dry granular, dry granular is crossed into 16 mesh sieves, carries out whole grain；
Secondary blend step：Dry granular after the magnesium stearate of formula ratio and whole grain is mixed, obtains the second mixture；
Forming step：Second mixture is placed in closed rotary pelleting machine (special-shaped punch die), carries out tabletting, 0.6g/
Piece, once piece weight is claimed per 15min, controls average piece to focus in ± the 5% of default piece weight, hardness is controlled in 7-9 kilograms, tabletting
After, contained and be capped with the turnover barrel of dried and clean and sealed, weighed, bucket outer patch distinguishing mark；
Coating steps (embodiment 5 omits this step)：Stomach dissolution type pharmaceutical films are coated premixing auxiliary material first, and (hydroxypropyl first is fine
Dimension element, polyethylene glycol, titanium dioxide and Brown Ferric Oxide) accurately claim by the requirement of formula solid content 8% and technique gain in weight 3%
Amount；Then 50% ethanol solution is configured to edible alcohol and purified water, 50% ethanol solution of precise is spare；Then will
Stomach dissolution type film-coating premixing auxiliary material is poured slowly into 50% solution, stirring while adding, is at the uniform velocity stirred, and is configured to solid content and is
8% uniform coating solution；
After label (the second mixture after shaping) sampling Detection qualification, film coating in high-efficiency coating machine is put.Tried outside machine
Spray gun, starts into atomization, it is desirable to choice refreshments：Preheating time 1min, rotating speed 6r/min, 65 DEG C of design temperature, piece bed tempertaure 38-40
DEG C, 65 DEG C of inlet air temperature, 40 DEG C of leaving air temp, throw 20cm.Coating process operating personnel cannot leave, concern temperature, revolution,
Spray gun is atomized situation, cannot pause halfway；Before off the pot, stop heating, turn 20min, revolution 3r/ again after being cooled to room temperature
min；Finally dress cloth bag carries out the piece 24h that dries in the air, and is put into silica-gel desiccant, barrelling is to be packed.
Effect assessment and performance detection
1st, blood fat experiment is adjusted
Test method：By healthy adult Kunming male SD rat 250, after balance feeds 5d, tail blood is taken, measure serum is total
Cholesterol (TC) and serum levels of triglyceride (TG).Filter out 150 that weight is 150-200g to be grouped at random, every group 30
Only, every 10 of group Inner is respectively low dose group (0.5g/kg.bw), middle dose group (1.0g/kg.bw) and high dose group (3.0g/
Kg.bw), gavage amount is calculated according to 1ml/100g weight, once a day, continuous 28 days, is taken tail hematometry indices, is counted respectively
The down ratio of TC and TG is calculated, the result is shown in table 2 below.
The reducing blood lipid test result record sheet of the ginkgo leaf monascus health product of 2 embodiment 1-5 of table
Record from table 2, according to《Function of health food assessment process and the method for inspection》Defined evaluation criterion, SD
For rat after the ginkgo leaf monascus health product of embodiment 1-5 is taken, TC and TG values have decline, although the ginkgo leaf of embodiment 5
Monascus health product is not coated, as long as but preserve good, do not interfere with its effect.
The above embodiment is only the preferred embodiment of the present invention, it is impossible to the scope of protection of the invention is limited with this,
The change and replacement for any unsubstantiality that those skilled in the art is done on the basis of the present invention belong to institute of the present invention
Claimed scope.
Claims (10)
1. a kind of ginkgo leaf monascus health product, it is characterised in that including following components in percentage by weight：
40-60 parts of ginkgo biloba p.e；120-170 parts of red yeast rice；140-210 parts of starch；
80-130 parts of maltodextrin；75-130 parts of D-sorbite；7-15 parts of magnesium stearate.
2. ginkgo leaf monascus health product as claimed in claim 1, it is characterised in that below in percentage by weight
Component：
45-55 parts of ginkgo biloba p.e；130-160 parts of red yeast rice；150-200 parts of starch；
90-120 parts of maltodextrin；85-120 parts of D-sorbite；8-13 parts of magnesium stearate.
3. ginkgo leaf monascus health product as claimed in claim 1 or 2, it is characterised in that it is pre- to further include 13-23 parts of film coatings
Mixture.
4. ginkgo leaf monascus health product as claimed in claim 3, it is characterised in that the film coating pre-mix dose is prepared into
Dividing includes：Hydroxypropyl methylcellulose, polyethylene glycol, titanium dioxide and Brown Ferric Oxide.
5. ginkgo leaf monascus health product as claimed in claim 1 or 2, it is characterised in that the ginkgo leaf monascus health product
Formulation is：Pulvis, tablet, granule, capsule, solution, emulsion or supensoid agent.
A kind of 6. preparation method of ginkgo leaf monascus health product as claimed in claim 1 or 2, it is characterised in that including：
Batch mixing step：The ginkgo biloba p.e of formula ratio, red yeast rice, starch, maltodextrin and D-sorbite are uniformly mixed,
Obtain the first mixture；
Softwood step processed：Add water in first mixture, while adding waterside to stir, obtain softwood；
Granulation step：The softwood is prepared into graininess, obtains wet grain；
Drying steps：The wet grain is dried, obtains dry granular；
Secondary blend step：The magnesium stearate of formula ratio and the dry granular are mixed, obtain the second mixture；
Forming step：Second mixture is prepared into preset shape, obtains the ginkgo leaf monascus health product.
7. the preparation method of ginkgo leaf monascus health product as claimed in claim 6, it is characterised in that further include sifting step：
Ginkgo biloba p.e, red yeast rice, starch, maltodextrin and D-sorbite are crossed into 80 mesh sieves respectively, then claimed respectively according to formula ratio
Above-mentioned each component is taken, in case into a batch mixing step.
8. the preparation method of ginkgo leaf monascus health product as claimed in claim 6, it is characterised in that further include whole grain step：
After the drying steps obtain dry granular, the dry granular is crossed into 16 mesh sieves, whole grain is carried out, enters the secondary mixing after whole grain
Step.
9. the preparation method of ginkgo leaf monascus health product as claimed in claim 6, it is characterised in that walked in a batch mixing
In rapid, the ginkgo biloba p.e of formula ratio, red yeast rice, starch, maltodextrin and D-sorbite are put into two-dimensional motion mixer,
Mix 18-22min；
In the softwood step processed, first mixture is added in trough type mixing machine, then adds water, and side adds waterside
Stirring, obtains softwood；
In the granulation step, the softwood is placed in oscillating granulator, after 16 mesh nylon mesh, obtains wet grain；
In the drying steps, the wet grain is sent into HighefficientFluidbeddrier, it is 45-55 DEG C to control drying temperature, is done
The moisture of dry to wet grain stops drying when being down to less than 5%, obtains dry granular；
In the secondary blend step, the magnesium stearate of formula ratio and the dry granular are placed in mixer, mix 18-
22min, obtains the second mixture；
In the forming step, second mixture is placed in closed rotary pelleting machine, carries out tabletting, per 13-
17min claims once piece weight, controls average piece to focus in ± the 5% of default piece weight, hardness control terminates in 7-9 kilograms, tabletting.
10. the preparation method of ginkgo leaf monascus health product as claimed in claim 6, it is characterised in that further include coating steps：
50% ethanol solution is taken, film coating pre-mix dose is poured into 50% ethanol solution, it is stirring while adding, obtain coating solution；
The second mixture after the coating solution and shaping is placed in seed-coating machine, is coated, final ginkgo leaf red yeast rice is obtained and protects
Strong product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711003574.4A CN107952003A (en) | 2017-10-24 | 2017-10-24 | A kind of ginkgo leaf monascus health product and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711003574.4A CN107952003A (en) | 2017-10-24 | 2017-10-24 | A kind of ginkgo leaf monascus health product and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107952003A true CN107952003A (en) | 2018-04-24 |
Family
ID=61964064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711003574.4A Pending CN107952003A (en) | 2017-10-24 | 2017-10-24 | A kind of ginkgo leaf monascus health product and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107952003A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021090358A (en) * | 2019-12-06 | 2021-06-17 | 小林製薬株式会社 | tablet |
| CN114272223A (en) * | 2021-12-31 | 2022-04-05 | 江西樟树市正康医药生物科技有限公司 | Pseudo-ginseng red yeast rice ginkgo leaf capsule and production process thereof |
| JP2023166032A (en) * | 2022-04-28 | 2023-11-17 | 小林製薬株式会社 | solid preparation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167763A (en) * | 2007-09-29 | 2008-04-30 | 南京克温生物科技有限公司 | Monascus and total ginkgolide composition for preventing and treating cardiovascular and cerebrovascular diseases |
| CN104920762A (en) * | 2015-06-30 | 2015-09-23 | 福建德广中草药有限公司 | Huangjing Maka tablet sugar and production method thereof |
-
2017
- 2017-10-24 CN CN201711003574.4A patent/CN107952003A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101167763A (en) * | 2007-09-29 | 2008-04-30 | 南京克温生物科技有限公司 | Monascus and total ginkgolide composition for preventing and treating cardiovascular and cerebrovascular diseases |
| CN104920762A (en) * | 2015-06-30 | 2015-09-23 | 福建德广中草药有限公司 | Huangjing Maka tablet sugar and production method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021090358A (en) * | 2019-12-06 | 2021-06-17 | 小林製薬株式会社 | tablet |
| JP7545204B2 (en) | 2019-12-06 | 2024-09-04 | 小林製薬株式会社 | tablet |
| CN114272223A (en) * | 2021-12-31 | 2022-04-05 | 江西樟树市正康医药生物科技有限公司 | Pseudo-ginseng red yeast rice ginkgo leaf capsule and production process thereof |
| CN114272223B (en) * | 2021-12-31 | 2023-07-07 | 江西樟树市正康医药生物科技有限公司 | Notoginseng red yeast rice ginkgo leaf capsule and its production process |
| JP2023166032A (en) * | 2022-04-28 | 2023-11-17 | 小林製薬株式会社 | solid preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5439366B2 (en) | Cellulose powder excellent in segregation preventing effect and composition thereof | |
| CN107875136B (en) | Amoxicillin medicinal preparation and preparation method thereof | |
| CN107952003A (en) | A kind of ginkgo leaf monascus health product and preparation method thereof | |
| JPH03236326A (en) | Direct compression cholestylamine tablet and its solvent-free protective | |
| AU2006319077B2 (en) | Slow-release composition, method for the preparation thereof, and use of the same | |
| EP2470165B1 (en) | Film coating composition from solid powder compounds | |
| CN106138087A (en) | A kind of dimension D calcium composition chewable tablet and preparation method thereof | |
| JPH01165530A (en) | Preparation of coated medicine | |
| CN104888228A (en) | Sorafenib tosylate solid dispersion body and preparation method thereof | |
| JP7332549B2 (en) | How to suppress mount occurrence | |
| CN104968335A (en) | Novel fast-dissolving granule formulation having improved solubility | |
| CN107812195A (en) | The stabilizing pharmaceutical composition of (6S) 5 methyl tetrahydrofolate calcium salt | |
| WO2012120364A2 (en) | Novel immediate release film coating compositions | |
| WO2020202598A1 (en) | Cellulose powder, tablet, and tablet production method | |
| JP2018002695A (en) | Crystalline cellulose mixed powder, composition, and method for producing molding | |
| WO2021090422A1 (en) | Cellulose composition and tablet | |
| CN110721249A (en) | Preparation method of grape seed essence tablet | |
| CN104055814B (en) | A kind of preparation method of American Ginseng broken wall preparation | |
| CN104055820B (en) | A kind of Herba Saussureae Involueratae broken wall preparation | |
| TWI402084B (en) | Microcapsules and method of preparing the same | |
| JP2003144528A (en) | Multilayer tablet and manufacturing method thereof | |
| CN113456639A (en) | Anti-arrhythmia pharmaceutical composition and preparation method thereof | |
| WO2019130701A1 (en) | Cellulose powder | |
| CN106361783A (en) | Ginkgo leaf tablet composition and preparation method thereof | |
| RU2798266C1 (en) | Cellulose-containing composition and tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180424 |
|
| RJ01 | Rejection of invention patent application after publication |